论文部分内容阅读
目的观察PC细胞来源的致瘤生长因子(PCDGF)在非小细胞肺癌(NSCLC)患者和正常人血清中的表达差异,及其与化疗疗效的关系。方法44例晚期初治的NSCLC患者和30例健康成人静脉血,采用PCDGF单抗作为一抗,随机选择部分样本进行Western blot观察电泳印迹;全部标本进行ELISA检测,比较PCDGF在NSCLC患者及正常人血清中的表达差异,分析NSCLC患者血清中PCDGF的表达差异与化疗疗效的关系。结果Western blot结果显示,在NSCLC患者和正常人血清中存在PCDGF的表达,NSCLC患者表达高于正常人。ELISA检测结果显示,NSCLC患者血清PCDGF(P<0．01)表达显著高于健康成人;化疗抗拒者的PCDGF表达高于正常人(P<0．01),化疗敏感者的PCDGF表达显著高于正常人(P<0．01);化疗抗拒血清PCDGF表达高于化疗敏感者(P< 0．05)。结论PCDGF在NSCLC患者血清中的高表达可能是NSCLC侵袭转移和增殖活跃的指标,其表达强度可能与化疗疗效相关,提示可能对铂类为主的化疗方案耐药。
Objective To investigate the difference of PCDGF expression in serum of patients with non-small cell lung cancer (NSCLC) and normal human and its relationship with chemotherapy efficacy. Methods Forty-four patients with newly diagnosed NSCLC and 30 healthy adults received PCDGF monoclonal antibody as a primary antibody. Some samples were randomly selected for Western blotting. Western blotting was performed on all samples. ELISA was used to detect PCDGF in NSCLC patients and normal controls Serum differences in the expression of NSCLC patients with serum PCDGF expression differences and the relationship between the efficacy of chemotherapy. Results The result of Western blot showed that the expression of PCDGF existed in serum of NSCLC patients and normal people, and the expression of PCDGF in NSCLC patients was higher than that in normal people. The results of ELISA showed that the expression of PCDGF in NSCLC patients was significantly higher than that in healthy adults (P <0.01), and the expression of PCDGF in chemoresistant patients was significantly higher than that in normal people (P <0.01). The expression of PCDGF in serum of chemotherapy-resistant group was higher than that of chemotherapy-sensitive group (P <0.05). Conclusion The high expression of PCDGF in serum of patients with NSCLC may be an indicator of invasion, metastasis and proliferation of NSCLC. The expression intensity of PCDGF may be related to the chemotherapy efficacy, suggesting that it may be resistant to platinum-based chemotherapy.